Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 82 entries
Sorted by: Best Match Show Resources per page
Editorial.

Bailliere's best practice & research. Clinical haematology

Delahunty M.
PMID: 11080448
Baillieres Best Pract Res Clin Haematol. 1999 Mar;12(1):XI. doi: 10.1053/beha.1999.0001.

No abstract available.

Cite
Delahunty M. Editorial. Baillieres Best Pract Res Clin Haematol. 1999;12(1):XIdoi: 10.1053/beha.1999.0001.
Delahunty, M. (1999). Editorial. Bailliere's best practice & research. Clinical haematology, 12(1), XI. https://doi.org/10.1053/beha.1999.0001
Delahunty. "Editorial." Bailliere's best practice & research. Clinical haematology vol. 12,1 (1999): XI. doi: https://doi.org/10.1053/beha.1999.0001
Delahunty M. Editorial. Baillieres Best Pract Res Clin Haematol. 1999 Mar;12(1):XI. doi: 10.1053/beha.1999.0001. PMID: 11080448.
Copy Download .nbib Format: NLM
Have any strategies in Ph-like ALL been shown to be effective?.

Best practice & research. Clinical haematology

Aldoss I, Advani AS.
PMID: 33762097
Best Pract Res Clin Haematol. 2021 Mar;34(1):101242. doi: 10.1016/j.beha.2021.101242. Epub 2021 Jan 11.

Philadelphia-like (Ph-like) acute lymphoblastic leukemia (ALL) is a high-risk subset of B-cell ALL characterized by high rates of treatment failure. Unsatisfactory outcomes with frontline therapy in adults with Ph-like ALL have been observed irrespective of the employed regimen, including...

Cite
Aldoss I, Advani AS. Have any strategies in Ph-like ALL been shown to be effective?. Best Pract Res Clin Haematol. 2021;34(1):101242doi: 10.1016/j.beha.2021.101242.
Aldoss, I., & Advani, A. S. (2021). Have any strategies in Ph-like ALL been shown to be effective?. Best practice & research. Clinical haematology, 34(1), 101242. https://doi.org/10.1016/j.beha.2021.101242
Aldoss, Ibrahim, and Advani, Anjali S. "Have any strategies in Ph-like ALL been shown to be effective?." Best practice & research. Clinical haematology vol. 34,1 (2021): 101242. doi: https://doi.org/10.1016/j.beha.2021.101242
Aldoss I, Advani AS. Have any strategies in Ph-like ALL been shown to be effective?. Best Pract Res Clin Haematol. 2021 Mar;34(1):101242. doi: 10.1016/j.beha.2021.101242. Epub 2021 Jan 11. PMID: 33762097.
Copy Download .nbib Format: NLM
How old is too old for a transplant?.

Best practice & research. Clinical haematology

Weisdorf D.
PMID: 33762098
Best Pract Res Clin Haematol. 2021 Mar;34(1):101243. doi: 10.1016/j.beha.2021.101243. Epub 2021 Jan 12.

Allogeneic transplantation remains the most definitive curative option for patients with acute myeloid leukemia (AML). However, given the median age of diagnosis of AML in the late 60s, patients and clinicians have been reluctant to offer transplant to many...

Cite
Weisdorf D. How old is too old for a transplant?. Best Pract Res Clin Haematol. 2021;34(1):101243doi: 10.1016/j.beha.2021.101243.
Weisdorf, D. (2021). How old is too old for a transplant?. Best practice & research. Clinical haematology, 34(1), 101243. https://doi.org/10.1016/j.beha.2021.101243
Weisdorf, Daniel. "How old is too old for a transplant?." Best practice & research. Clinical haematology vol. 34,1 (2021): 101243. doi: https://doi.org/10.1016/j.beha.2021.101243
Weisdorf D. How old is too old for a transplant?. Best Pract Res Clin Haematol. 2021 Mar;34(1):101243. doi: 10.1016/j.beha.2021.101243. Epub 2021 Jan 12. PMID: 33762098; PMCID: PMC7994544.
Copy Download .nbib Format: NLM
Immune checkpoint inhibitors in acute myeloid leukemia.

Best practice & research. Clinical haematology

Daver N.
PMID: 33762102
Best Pract Res Clin Haematol. 2021 Mar;34(1):101247. doi: 10.1016/j.beha.2021.101247. Epub 2021 Jan 30.

Understanding the immune biology of AML and designing rational approaches to target or harness the immune environment to improve outcomes is an area of intense research in AML. There are two primary immune checkpoint harnessing modalities under clinical evaluation...

Cite
Daver N. Immune checkpoint inhibitors in acute myeloid leukemia. Best Pract Res Clin Haematol. 2021;34(1):101247doi: 10.1016/j.beha.2021.101247.
Daver, N. (2021). Immune checkpoint inhibitors in acute myeloid leukemia. Best practice & research. Clinical haematology, 34(1), 101247. https://doi.org/10.1016/j.beha.2021.101247
Daver, Naval. "Immune checkpoint inhibitors in acute myeloid leukemia." Best practice & research. Clinical haematology vol. 34,1 (2021): 101247. doi: https://doi.org/10.1016/j.beha.2021.101247
Daver N. Immune checkpoint inhibitors in acute myeloid leukemia. Best Pract Res Clin Haematol. 2021 Mar;34(1):101247. doi: 10.1016/j.beha.2021.101247. Epub 2021 Jan 30. PMID: 33762102.
Copy Download .nbib Format: NLM
It is time to shift the treatment paradigm in myelodysplastic syndromes: A focus on novel developments and current investigational approaches exploring combinatorial therapy in high-risk MDS.

Best practice & research. Clinical haematology

Aguirre LE, Komrokji R, Padron E.
PMID: 34865697
Best Pract Res Clin Haematol. 2021 Dec;34(4):101325. doi: 10.1016/j.beha.2021.101325. Epub 2021 Oct 23.

Higher risk myelodysplastic syndromes are defined as a subset of disease with higher risk of AML transformation and poor overall survival. For decades, therapeutic options for high-risk MDS have been limited to allogeneic stem cell transplant (the only option...

Cite
Aguirre LE, Komrokji R, Padron E. It is time to shift the treatment paradigm in myelodysplastic syndromes: A focus on novel developments and current investigational approaches exploring combinatorial therapy in high-risk MDS. Best Pract Res Clin Haematol. 2021;34(4):101325doi: 10.1016/j.beha.2021.101325.
Aguirre, L. E., Komrokji, R., & Padron, E. (2021). It is time to shift the treatment paradigm in myelodysplastic syndromes: A focus on novel developments and current investigational approaches exploring combinatorial therapy in high-risk MDS. Best practice & research. Clinical haematology, 34(4), 101325. https://doi.org/10.1016/j.beha.2021.101325
Aguirre, Luis E, et al. "It is time to shift the treatment paradigm in myelodysplastic syndromes: A focus on novel developments and current investigational approaches exploring combinatorial therapy in high-risk MDS." Best practice & research. Clinical haematology vol. 34,4 (2021): 101325. doi: https://doi.org/10.1016/j.beha.2021.101325
Aguirre LE, Komrokji R, Padron E. It is time to shift the treatment paradigm in myelodysplastic syndromes: A focus on novel developments and current investigational approaches exploring combinatorial therapy in high-risk MDS. Best Pract Res Clin Haematol. 2021 Dec;34(4):101325. doi: 10.1016/j.beha.2021.101325. Epub 2021 Oct 23. PMID: 34865697.
Copy Download .nbib Format: NLM
How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)?.

Best practice & research. Clinical haematology

Steensma DP.
PMID: 34865699
Best Pract Res Clin Haematol. 2021 Dec;34(4):101327. doi: 10.1016/j.beha.2021.101327. Epub 2021 Oct 23.

Clonal hematopoiesis (CH) - a biological state in which one or a small number of hematopoietic stem or progenitor cells contribute disproportionately to blood cell production, usually as a result of somatic gene mutations in the stem cells -...

Cite
Steensma DP. How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)?. Best Pract Res Clin Haematol. 2021;34(4):101327doi: 10.1016/j.beha.2021.101327.
Steensma, D. P. (2021). How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)?. Best practice & research. Clinical haematology, 34(4), 101327. https://doi.org/10.1016/j.beha.2021.101327
Steensma, David P. "How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)?." Best practice & research. Clinical haematology vol. 34,4 (2021): 101327. doi: https://doi.org/10.1016/j.beha.2021.101327
Steensma DP. How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)?. Best Pract Res Clin Haematol. 2021 Dec;34(4):101327. doi: 10.1016/j.beha.2021.101327. Epub 2021 Oct 23. PMID: 34865699.
Copy Download .nbib Format: NLM
Redefining the biological basis of lineage-ambiguous leukemia through genomics: BCL11B deregulation in acute leukemias of ambiguous lineage.

Best practice & research. Clinical haematology

Montefiori LE, Mullighan CG.
PMID: 34865701
Best Pract Res Clin Haematol. 2021 Dec;34(4):101329. doi: 10.1016/j.beha.2021.101329. Epub 2021 Oct 23.

Acute leukemias of ambiguous lineage (ALAL), including mixed phenotype acute leukemia (MPAL) and related entities such as early T-cell precursor acute leukemia (ETP-ALL), remain diagnostic and clinical challenges due to limited understanding of pathogenesis, reliance of immunophenotyping to classify...

Cite
Montefiori LE, Mullighan CG. Redefining the biological basis of lineage-ambiguous leukemia through genomics: BCL11B deregulation in acute leukemias of ambiguous lineage. Best Pract Res Clin Haematol. 2021;34(4):101329doi: 10.1016/j.beha.2021.101329.
Montefiori, L. E., & Mullighan, C. G. (2021). Redefining the biological basis of lineage-ambiguous leukemia through genomics: BCL11B deregulation in acute leukemias of ambiguous lineage. Best practice & research. Clinical haematology, 34(4), 101329. https://doi.org/10.1016/j.beha.2021.101329
Montefiori, Lindsey E, and Mullighan, Charles G. "Redefining the biological basis of lineage-ambiguous leukemia through genomics: BCL11B deregulation in acute leukemias of ambiguous lineage." Best practice & research. Clinical haematology vol. 34,4 (2021): 101329. doi: https://doi.org/10.1016/j.beha.2021.101329
Montefiori LE, Mullighan CG. Redefining the biological basis of lineage-ambiguous leukemia through genomics: BCL11B deregulation in acute leukemias of ambiguous lineage. Best Pract Res Clin Haematol. 2021 Dec;34(4):101329. doi: 10.1016/j.beha.2021.101329. Epub 2021 Oct 23. PMID: 34865701; PMCID: PMC8649174.
Copy Download .nbib Format: NLM
Current status of pretransplant intensive chemotherapy or hypomethylating agents for myelodysplastic syndrome.

Best practice & research. Clinical haematology

Niederwieser C, Kröger N.
PMID: 34865704
Best Pract Res Clin Haematol. 2021 Dec;34(4):101332. doi: 10.1016/j.beha.2021.101332. Epub 2021 Oct 28.

Myelodysplastic syndrome is a heterogeneous disease with survival probabilities ranging from a few months to several years. Allogeneic hematopoietic cell transplantation (HCT) remains the only curative treatment. Although access (up to 75 years) and outcome of HCT have improved...

Cite
Niederwieser C, Kröger N. Current status of pretransplant intensive chemotherapy or hypomethylating agents for myelodysplastic syndrome. Best Pract Res Clin Haematol. 2021;34(4):101332doi: 10.1016/j.beha.2021.101332.
Niederwieser, C., & Kröger, N. (2021). Current status of pretransplant intensive chemotherapy or hypomethylating agents for myelodysplastic syndrome. Best practice & research. Clinical haematology, 34(4), 101332. https://doi.org/10.1016/j.beha.2021.101332
Niederwieser, Christian, and Kröger, Nicolaus. "Current status of pretransplant intensive chemotherapy or hypomethylating agents for myelodysplastic syndrome." Best practice & research. Clinical haematology vol. 34,4 (2021): 101332. doi: https://doi.org/10.1016/j.beha.2021.101332
Niederwieser C, Kröger N. Current status of pretransplant intensive chemotherapy or hypomethylating agents for myelodysplastic syndrome. Best Pract Res Clin Haematol. 2021 Dec;34(4):101332. doi: 10.1016/j.beha.2021.101332. Epub 2021 Oct 28. PMID: 34865704.
Copy Download .nbib Format: NLM
Changing trends in the therapy of acute myeloid leukemia.

Best practice & research. Clinical haematology

Rowe JM.
PMID: 34865705
Best Pract Res Clin Haematol. 2021 Dec;34(4):101333. doi: 10.1016/j.beha.2021.101333. Epub 2021 Oct 29.

There has been remarkable progress in the treatment of acute myeloid leukemia (AML) which has spanned 5 decades. The changing trends have led to new approaches and significant improvement in outcomes. This review has summarized the historical insights that...

Cite
Rowe JM. Changing trends in the therapy of acute myeloid leukemia. Best Pract Res Clin Haematol. 2021;34(4):101333doi: 10.1016/j.beha.2021.101333.
Rowe, J. M. (2021). Changing trends in the therapy of acute myeloid leukemia. Best practice & research. Clinical haematology, 34(4), 101333. https://doi.org/10.1016/j.beha.2021.101333
Rowe, Jacob M. "Changing trends in the therapy of acute myeloid leukemia." Best practice & research. Clinical haematology vol. 34,4 (2021): 101333. doi: https://doi.org/10.1016/j.beha.2021.101333
Rowe JM. Changing trends in the therapy of acute myeloid leukemia. Best Pract Res Clin Haematol. 2021 Dec;34(4):101333. doi: 10.1016/j.beha.2021.101333. Epub 2021 Oct 29. PMID: 34865705.
Copy Download .nbib Format: NLM
Important factors improving outcome of young adults with acute lymphoblastic leukemia (ALL).

Best practice & research. Clinical haematology

Bleyer A.
PMID: 34865694
Best Pract Res Clin Haematol. 2021 Dec;34(4):101322. doi: 10.1016/j.beha.2021.101322. Epub 2021 Oct 27.

Four categories of important factors improving outcome of young adults and older adolescents with acute lymphoblastic leukemia (ALL) are biologic type, clinical trials, pediatric vs. adult treatment regimen, and psychosocial challenges. Overall, the outcome of ALL in the age...

Cite
Bleyer A. Important factors improving outcome of young adults with acute lymphoblastic leukemia (ALL). Best Pract Res Clin Haematol. 2021;34(4):101322doi: 10.1016/j.beha.2021.101322.
Bleyer, A. (2021). Important factors improving outcome of young adults with acute lymphoblastic leukemia (ALL). Best practice & research. Clinical haematology, 34(4), 101322. https://doi.org/10.1016/j.beha.2021.101322
Bleyer, Archie. "Important factors improving outcome of young adults with acute lymphoblastic leukemia (ALL)." Best practice & research. Clinical haematology vol. 34,4 (2021): 101322. doi: https://doi.org/10.1016/j.beha.2021.101322
Bleyer A. Important factors improving outcome of young adults with acute lymphoblastic leukemia (ALL). Best Pract Res Clin Haematol. 2021 Dec;34(4):101322. doi: 10.1016/j.beha.2021.101322. Epub 2021 Oct 27. PMID: 34865694.
Copy Download .nbib Format: NLM
Is the current consolidation regimen for AML evidence-based?.

Best practice & research. Clinical haematology

Luger SM.
PMID: 34865706
Best Pract Res Clin Haematol. 2021 Dec;34(4):101334. doi: 10.1016/j.beha.2021.101334. Epub 2021 Nov 03.

Current standard of care for consolidation therapy for AML varies based on age and induction regimen, among other factors. Many trials have sought to determine the optimal dose, number of cycles, and schedule for consolidation with cytarabine. For AML...

Cite
Luger SM. Is the current consolidation regimen for AML evidence-based?. Best Pract Res Clin Haematol. 2021;34(4):101334doi: 10.1016/j.beha.2021.101334.
Luger, S. M. (2021). Is the current consolidation regimen for AML evidence-based?. Best practice & research. Clinical haematology, 34(4), 101334. https://doi.org/10.1016/j.beha.2021.101334
Luger, Selina M. "Is the current consolidation regimen for AML evidence-based?." Best practice & research. Clinical haematology vol. 34,4 (2021): 101334. doi: https://doi.org/10.1016/j.beha.2021.101334
Luger SM. Is the current consolidation regimen for AML evidence-based?. Best Pract Res Clin Haematol. 2021 Dec;34(4):101334. doi: 10.1016/j.beha.2021.101334. Epub 2021 Nov 03. PMID: 34865706.
Copy Download .nbib Format: NLM
Thrombopoietin receptor agonists for marrow failure: A concise clinical review.

Best practice & research. Clinical haematology

Kapoor S, Champion G, Olnes MJ.
PMID: 34404526
Best Pract Res Clin Haematol. 2021 Jun;34(2):101274. doi: 10.1016/j.beha.2021.101274. Epub 2021 Jun 02.

Bone marrow failure is characterized by a disruption of hematopoietic stem cell (HSC) homeostasis and function, which causes decreased blood counts. Germline and somatic mutations within HSCs and immune dysregulation contribute to the pathogenesis of marrow failure. Allogeneic HSC...

Cite
Kapoor S, Champion G, Olnes MJ. Thrombopoietin receptor agonists for marrow failure: A concise clinical review. Best Pract Res Clin Haematol. 2021;34(2):101274doi: 10.1016/j.beha.2021.101274.
Kapoor, S., Champion, G., & Olnes, M. J. (2021). Thrombopoietin receptor agonists for marrow failure: A concise clinical review. Best practice & research. Clinical haematology, 34(2), 101274. https://doi.org/10.1016/j.beha.2021.101274
Kapoor, Sargam, et al. "Thrombopoietin receptor agonists for marrow failure: A concise clinical review." Best practice & research. Clinical haematology vol. 34,2 (2021): 101274. doi: https://doi.org/10.1016/j.beha.2021.101274
Kapoor S, Champion G, Olnes MJ. Thrombopoietin receptor agonists for marrow failure: A concise clinical review. Best Pract Res Clin Haematol. 2021 Jun;34(2):101274. doi: 10.1016/j.beha.2021.101274. Epub 2021 Jun 02. PMID: 34404526.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 82 entries